CRDF vs. PHVS, CRMD, AKBA, OCS, LENZ, PRAX, ZYME, CMRX, CDMO, and NUVB
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Pharvaris (PHVS), CorMedix (CRMD), Akebia Therapeutics (AKBA), Oculis (OCS), LENZ Therapeutics (LENZ), Praxis Precision Medicines (PRAX), Zymeworks (ZYME), Chimerix (CMRX), Avid Bioservices (CDMO), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry.
Cardiff Oncology vs. Its Competitors
Pharvaris (NASDAQ:PHVS) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership.
Pharvaris presently has a consensus price target of $36.20, indicating a potential upside of 112.32%. Cardiff Oncology has a consensus price target of $12.00, indicating a potential upside of 210.08%. Given Cardiff Oncology's higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Pharvaris.
Pharvaris has a net margin of 0.00% compared to Cardiff Oncology's net margin of -6,238.17%. Pharvaris' return on equity of -38.52% beat Cardiff Oncology's return on equity.
Pharvaris has a beta of -2.86, meaning that its stock price is 386% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.
Cardiff Oncology has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
In the previous week, Pharvaris had 17 more articles in the media than Cardiff Oncology. MarketBeat recorded 21 mentions for Pharvaris and 4 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 1.71 beat Pharvaris' score of 0.62 indicating that Cardiff Oncology is being referred to more favorably in the news media.
Cardiff Oncology received 3 more outperform votes than Pharvaris when rated by MarketBeat users. However, 67.80% of users gave Pharvaris an outperform vote while only 65.15% of users gave Cardiff Oncology an outperform vote.
16.3% of Cardiff Oncology shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by company insiders. Comparatively, 7.7% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Cardiff Oncology beats Pharvaris on 9 of the 16 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:CRDF) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy CRDF Stock Free CRDF Stock Alerts